ReMix Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for ReMix Therapeutics.

ReMix Therapeutics Overview

About ReMix Therapeutics

ReMix Therapeutics Inc is a clinical-stage biotechnology company focused on developing small molecule therapeutics to modulate ribonucleic acid (RNA) processing and address the underlying drivers of disease. Its flagship program, REM-422, is an investigational oral mRNA degrader targeting the MYB oncogenic transcription factor, which is being developed for the treatment of adenoid cystic carcinoma (ACC), acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and other cancers.


Founded

2019

HQ

United States

Employees

37

Financials (Last FY)

Revenue: -
Net Income: -

Market Cap

-

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

ReMix Therapeutics Stock Performance

ReMix Therapeutics has current market cap of -.

Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
------

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

ReMix Therapeutics Valuation Multiples

ReMix Therapeutics Financial Valuation Multiples

As of November 10, 2026, ReMix Therapeutics has market cap of -.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified ReMix Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

ReMix Therapeutics Competitors

ReMix Therapeutics competitors include Eli Lilly, Johnson & Johnson, AbbVie, Roche, Merck, Novartis, AstraZeneca, Amgen, Gilead Sciences and Novo Nordisk.

Most ReMix Therapeutics public comparables operate across Biopharmaceuticals, Diagnostics & Genomics, BioTech and DeepTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Eli Lilly$65B$28B20.0x14.9x47.0x31.3x
Johnson & Johnson$94B$40B7.5x7.0x17.7x19.2x
AbbVie$61B$17B9.6x8.8x33.9x18.7x
Roche$77B$26B5.5x5.4x16.1x13.6x
Merck$65B$28B6.3x6.1x14.7x23.3x
Novartis$57B$22B6.1x6.1x15.9x14.9x
AstraZeneca$59B$19B5.4x5.1x16.5x14.1x
Amgen$37B$17B8.0x7.5x17.4x16.6x

This data is available for Pro users. Sign up to see all ReMix Therapeutics competitors and their valuation data.

Start Free Trial

ReMix Therapeutics VC Funding History

Before going public, ReMix Therapeutics raised $211M in total equity funding, across 4 rounds.


ReMix Therapeutics Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jan-24Undisclosed stageWillett Advisors LLC; The Column Group; Alexandria Venture Investments; Casdin Capital; WTT Investment; Foresite Capital; Atlas Venture; Surveyor Capital; ARCH Venture Partners$60M-Remix Therapeutics is a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and treat disease through its proprietary REMaster platform. The platform leverages data analytics, machine learning, bespoke high-throughput screening technologies, and next-generation chemistry to identify and target RNA processing steps to degrade mRNA, enhance RNA production, or correct RNA dysregulation in disease. The company's lead candidate, REM-422, was expected to enter Phase 1 clinical studies in 2024 for the treatment of recurrent or metastatic adenoid cystic carcinoma and acute myeloid leukemia/myelodysplastic syndromes. In January 2024, Remix closed a Series C financing round of $60 million led by The Column Group with participation from existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, ARCH Venture Partners, Casdin Capital, and Surveyor (a Citadel company), along with new investors WTT Investment and Willett Advisors. Simultaneously, the company announced a collaboration with Roche involving a $30 million upfront payment, with up to $1 billion in potential milestone payments and royalties, granting Roche exclusive rights to discover and develop small molecule therapeutics for specific targets using Remix's REMaster platform while Remix retains in-house development of its own programs.
May-22Series BThe Column Group; Alexandria Venture Investments; Casdin Capital; Foresite Capital; Atlas Venture; Surveyor Capital; ARCH Venture Partners$70M-Remix Therapeutics, a Massachusetts-based biotech company, raised $70 million in its Series B financing round on May 17, 2022, led by Surveyor Capital with participation from Foresite Capital, Atlas Venture, The Column Group, Arch Venture Partners, Alexandria Venture Investments, and Casdin Capital. The company develops novel small molecule therapies designed to reprogram RNA processing to treat diseases in new ways, leveraging its REMaster technology platform to advance a pipeline of RNA processing targeted therapeutics. The new capital was intended to support platform development and pipeline progression. CEO Peter Smith highlighted the financing as a reflection of significant progress in advancing the novel platform and programs modulating RNA processing. Gunderson Dettmer represented Remix in the transaction. The company has continued raising capital, including a Series C of $60M on January 3, 2024, from many of the same investors plus others, bringing total funding to $211M over four rounds.
Dec-20Series AThe Column Group; Alexandria Venture Investments; Foresite Capital; Atlas Venture; ARCH Venture Partners$65M-Remix Therapeutics, a biotechnology company based in Cambridge, Massachusetts, launched in December 2020 with $81 million in total financing, comprising $16 million in seed funding from Atlas Venture and The Column Group, plus a $65 million Series A round led by Foresite Capital, with participation from Alexandria Venture Investments and ARCH Venture Partners. The funds support development of the company's proprietary REMaster technology platform, which uses data analytics, high-throughput screening, and advanced chemistry to identify and target RNA processing steps, aiming to enhance or eliminate protein function for treating diseases like cancers, central nervous system disorders, and rare diseases. The REMaster platform enables precise reprogramming of RNA processing to address underlying disease drivers, positioning Remix to advance a pipeline of small-molecule therapeutics. At launch, the company had an 18-person team focused on scientists in chemistry, data science, and RNA biology, with plans to expand for platform building and clinical trial preparation. Leadership includes co-founder Peter Smith, PhD, as president and chief scientific officer, and Heather Wasserman as chief business and chief operating officer. Subsequent developments include a $70 million Series B in May 2022 and a $60 million venture round in early 2024, bringing total financing to $201 million before a potential $1 billion Roche collaboration. Investors highlighted the platform's potential across broad disease areas, with board members from Atlas Venture, Foresite Capital, and The Column Group.
Jan-19SeedThe Column Group; Atlas Venture$16M--

Acquisitions by ReMix Therapeutics

ReMix Therapeutics has acquired 1 company to date.

Last acquisition by ReMix Therapeutics was on June 23rd 2026. ReMix Therapeutics acquired Passage Bio for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by ReMix Therapeutics

Passage Bio
Description
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
HQ CountryUnited States
HQ City
Philadelphia, PA
Deal Date23 Jun 2026
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all ReMix Therapeutics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About ReMix Therapeutics

When was ReMix Therapeutics founded?ReMix Therapeutics was founded in 2019.
Where is ReMix Therapeutics headquartered?ReMix Therapeutics is headquartered in United States.
How many employees does ReMix Therapeutics have?As of today, ReMix Therapeutics has over 37 employees.
Is ReMix Therapeutics publicly listed?Yes, ReMix Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of ReMix Therapeutics?ReMix Therapeutics trades under RMTX ticker.
When did ReMix Therapeutics go public?ReMix Therapeutics went public in 2050.
Who are competitors of ReMix Therapeutics?ReMix Therapeutics main competitors include Eli Lilly, Johnson & Johnson, AbbVie, Roche, Merck, Novartis, AstraZeneca, Amgen, Gilead Sciences, Novo Nordisk.
Is ReMix Therapeutics profitable?No, ReMix Therapeutics is not profitable.
How many companies ReMix Therapeutics has acquired to date?As of November 2026, ReMix Therapeutics has acquired 1 company.
What was the largest acquisition by ReMix Therapeutics?None of the M&A deals ReMix Therapeutics has completed have disclosed valuations.
What companies ReMix Therapeutics acquired?ReMix Therapeutics acquired Passage Bio.
In how many companies ReMix Therapeutics has invested to date?ReMix Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to ReMix Therapeutics

Lists including ReMix Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial